Thursday, September 30, 2021 4:48:15 PM
AGN is working toward the continued concepts of NDMA actions on the lungs. Now as both a CC remedy and for tumors due to some IL-6/low O2 data for Proof of Concept/whatever.
I should have referred to one of my previous posts re; REM/Wuhan V.I./Gilead/FDA/CCP. The post was supposed to be sadly funny.
BUT.
Ifenprodil 'may' have been a better treatment than REM, IMHFO. NA. Certainly does 'no damage' and 'may' have helped.
Few are arguing about the bad Safety record of Remdeathisnear.
PFE is working on a PFIzermectin type 'new drug' for COVID treatments.
No one is saying Ifenprodil treatments for Lung affected diseases may be un-Safe.?. "Powered' Phase 2 for Ifenprodil Chronic Cough CT.
Finally, we can expect better management handling of the paths forward. There are obvious improvements already.
There is strong support from AGN's SMEs. It's very encouraging to have our experts do the talking, in PRs ect, about continuous developments in the company's projects...GLTA...
Maybe LS* can do a PP until we get a BP partner's/sponsor's $$$.
Thanks for the past support from the 5...
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM